Marc Ernstoff, a physician who has pioneered immunotherapy research and treatments for cancer patients, said his work as a federal scientist proved untenable under the Trump administration. Philip Stewart, a Rocky Mountain Laboratories researcher focused on tick-borne diseases, said he retired two years earlier than planned because of hurdles that made it too challenging to…
BATON ROUGE, La. — The ambitious liver doctor would go just about anywhere in his home state to give people the hepatitis B vaccine. Bill Cassidy offered jabs to thousands of inmates at Louisiana’s maximum-security prison in the early 2000s. A decade before that, he set up vaccine clinics in middle schools, a model hailed…
Eli Lilly’s new Lilly Employer Connect platform offers employers more flexible access to obesity drugs like Zepbound, but experts say it represents only incremental progress. The post Lilly Employer Connect Adds Flexibility for Employers But Isn’t Revolutionary, Expert Says appeared first on MedCity News.
Healthcare AI startups are experimenting with pricing models that tie their costs to real-world results, such as completed tasks or improved patient outcomes. While investors see this as a way to prove value, many hospitals remain skeptical, preferring predictable pricing. The post AI Startups Are Tying Fees to Completed Tasks. Will Hospitals Buy In? appeared…
Most adult Medicaid enrollees who will be subject to new work requirements are already working but rely on Medicaid because their employers do not offer health coverage or they are not eligible for the coverage offered at their job. This analysis examines the availability of job-based insurance in 2024 for adult Medicaid workers ages 19…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
The Series B extension brings Atavistik Bio’s Series B financing to $160 million. The startup’s lead program is in development for hereditary hemorrhagic telangiectasia (HHT), an inherited bleeding disorder. The post Startup Atavistik Adds $40M for Clinical Trial in Rare Bleeding Disorder With No Approved Therapies appeared first on MedCity News.
[Sponsored] Healthcare executives spoke with MedCity News on how their businesses are using tech to shape the clinician and patient experience. The post How to Build Effective Referral Networks and Improve Patient Navigation [Video] appeared first on MedCity News.
This content is password-protected. To view it, please enter the password below. Password: The post Protected: Myth vs. Fact: The Operational Realities Shaping Sterile Processing Performance appeared first on Crothall Healthcare.
The move toward infusion centers as the preferred site of care is not a short-term response. It aligns with broader industry trends, including specialty drug pipelines that continue to favor infused biologics and a sustained rise in infusion demand. The post Why Hospital Outpatient Isn’t the Default for Long-Term Infusion Anymore appeared first on MedCity…